GLP-1 RAs Linked to Lower HR+ Breast Cancer Risk and Improved Survival

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have dominated clinical discussions regarding weight loss and metabolic health, but new data presented at the ASCO 2026 Annual Meeting suggest their utility may extend into the realm of oncology prophylaxis and survival.

A real-world analysis of nearly 150,000 women indicates that GLP-1 RA exposure is associated with a modest but significant reduction in incident hormone receptor-positive (HR+), HER2-negative breast cancer and a marked improvement in overall survival (OS) among non-diabetic women with an elevated body mass index (BMI).

The study, led by Zunairah Shah, MBBS, and colleagues at Roswell Park Comprehensive Cancer Center, sought to clarify the relationship between these increasingly popular agents and breast cancer outcomes. While obesity is a well-established risk factor for various malignancies, particularly postmenopausal breast cancer, the specific impact of GLP-1 RAs on cancer incidence and mortality in non-diabetic populations has remained largely unclear.

Study methodology and patient population

The researchers conducted a retrospective cohort study utilizing the TriNetX US Collaborative Network, a large real-world database. The study focused on a specific demographic: female patients with a BMI between 25 and 35 kg/m² who did not have a laboratory-defined diagnosis of diabetes (HbA1c <6.5%) and had no prior history of breast cancer.

To ensure a rigorous comparison, the researchers employed propensity score matching (PSM). This balanced two cohorts — those with GLP-1 RA exposure (n=74,354) and controls (n=74,355) — across several critical variables, including age, BMI, and the use of metformin or statins.

The cohorts were also matched for BRCA mutation status, hormonal contraceptive use, parity, breastfeeding history, and smoking status. For the purposes of the analysis, age was used as a proxy for menopausal status, with patients under 50 considered premenopausal and those 50 or older considered postmenopausal.

Key findings: Incidence and subtypes

The primary endpoint of the study was the incidence of HR+/HER2- breast cancer over a 36-month follow-up period. The data revealed that women in the GLP-1 RA group had a lower incidence proportion (0.29%) compared to the control group (0.33%). This represents a risk ratio (RR) of 0.88 (95% CI 0.77–0.99; P=0.046), indicating a modest but statistically significant reduction in the primary endpoint.

Interestingly, the protective effect appeared specific to the HR+/HER2- subtype. Secondary analyses evaluating other breast cancer subtypes — including HR+/HER2+, HR-/HER2+, and triple-negative breast cancer (TNBC) — did not show statistically significant differences between the GLP-1 RA and control cohorts.

The survival advantage

While the reduction in incidence was modest, the survival data were more pronounced. Across the entire cohort of 148,709 patients, the GLP-1 RA group demonstrated a significant overall survival advantage. The hazard ratio (HR) for OS was 0.75 (95% CI 0.65–0.86), meaning patients exposed to GLP-1 RAs had a 25% lower risk of death compared to their matched controls (P<0.0001).

This survival benefit was consistent across age-based menopausal proxies. In the premenopausal proxy group (age <50), the HR for OS was 0.71 (P=0.0004), while in the postmenopausal proxy group (age ≥50), the HR was 0.87 (P=0.0003). These findings suggest that the metabolic benefits or potential direct antitumor effects of GLP-1 RAs translate into a survival benefit regardless of the patient's hormonal stage.

Nursing implications and future directions

For oncology nurses, these findings provide critical context as more patients enter the clinic already utilizing GLP-1 RAs for weight management. While the study is retrospective and has limited follow-up, it provides real-world evidence that supports the continued investigation of these agents as a prophylactic strategy.

The researchers noted that it remains unclear whether these benefits are direct antitumor effects or indirect results mediated through weight loss and cardiometabolic risk reduction.

Reference

1. Shah Z, Hundal J, Afridi SS, et al. GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis. Poster presented at: ASCO 2026; May 29-June 2, 2026; Chicago, IL. Poster 509.